CMC, Bioprocessing & Scale-Up Blog - Smart Biotech Scientist

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Bioprocessing

Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 2

What happens between scientific discovery and clinical trials?

Bioprocessing

Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 1

Picture the difference between a “drug” and a true “product”.

Bioprocessing

Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 2

What if the biggest advancement in bioprocessing isn’t a new AI algorithm or cutting-edge bioreactor, but a renewed focus on the foundational skills that drive innovation—and a clear-eyed look at what AI can (and can’t) really do for the industry right now?

Bioprocessing

Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 1

How do you bridge the gap between cutting-edge industrial bioprocessing and the academic world tasked with training the next generation?

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Bioprocessing

Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

What if the difference between a seamless tech transfer and a costly setback isn’t your process, but how you orchestrate the people and details behind the scenes?

Bioprocessing

Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

Tech transfer in biotech can feel like a high-stakes gamble, balancing regulatory shifts, incomplete data, and mounting stakeholder pressure—all with timelines breathing down your neck.

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2

Are you struggling with the complexities of cell and gene therapy manufacturing and wondering how automation and digital solutions can truly make these life-saving therapies accessible to more people?

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1

Cell and gene therapies have opened the doors to personalized medicine, but manufacturing these complex therapies is filled with hidden process risks that can compromise efficacy and patient access.

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Dr. David Brühlmann

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Dr. David Brühlmann

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Dr. David Brühlmann

CMC and Bioprocess Blog

Bioprocessing

Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 2

Bioprocessing

Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing – Part 1

Bioprocessing

Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 2

Bioprocessing

Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore – Part 1

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Bioprocessing

Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

Bioprocessing

Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.